Coexistence of sarcoidosis and malignant lymphoproliferative disease (LD) has been reported sporadically for the last 50 years, but mostly during the last two decades (Table I ). The assessment of such reports is difficult. While LD is usually easy to verify, the presence of true sarcoidosis is often difficult to prove, even when clinicoradiographic findings compatible with sarcoidosis are supported by histologic evidence of non-caseating epitheliod cell granulomas (EPCG), since infectious agents and tissue irritants may induce similar histologic changes (Parkes, 1974; Sharma, 1984) . Further, the occasional occurrence of local sarcoid reactions in LD, particularly in Hodgkin's disease, complicates the issue (Kadin et al., 1971; Kim & Dorfman, 1974; Neiman, 1977) . Thus, regardless of whether sarcoidosis is presumed before or after the verification of LD, it may be argued that the latter disease is responsible for the occurrence of EPCG, particularly if both diseases are primarily located to the skin or the lymph nodes.
Under these circumstances any selection of reported cases of coexisting sarcoidosis and LD will be the result of a personal judgement. Table I presents 29 cases which the author tends to regard as genuine. However, there are some additional cases of LD localized to the skin in which it cannot be determined whether the occurrence of EPCG in the skin signifies concurrent sarcoidosis or a local sarcoid reaction (Pautrier, 1938; Kissel et al., 1962; Ackerman & Flaxman, 1970; Kahn et al., 1974) . Further, there are some reports in which coexistence of sarcoidosis and LD has been claimed although it is more likely that mere local sarcoid reactions have been observed (Hastings & Thompson, 1949; Wurm et al., 1958; Razis et al., 1959 (ii) The median age of the patients at onset of sarcoidosis is 41 years which is 10 years above the median age of unselected patients with sarcoidosis (Horwitz et al., 1967) . This is interesting because a late onset of sarcoidosis is quite often associated with a chronic active type of this disease. (iii) Hodgkin's disease occurs more frequently than expected if the association between sarcoidosis and the various types of LD were merely fortuitous.
Taken together, the three features mentioned above suggest the existence of a sarcoidosislymphoma syndrome which may evolve through an immunological mechanism. In order to characterize this proposed syndrome in more detail a further 17 cases of coexisting sarcoidosis and LD have been collected and analyzed.
Material and methods
The 17 cases of coexistent sarcoidosis and malignant LD (Table II) were found by following anamnestic indications of preceding sarcoidosis, uncovered at the time of diagnosis of the malignancy. However, cases 1 and 2 presented with Hodgkin's disease with lymph-node biopsies also containing EPCG, and clinical signs of sarcoidosis did not appear until 5 and 17 years later, respectively. Cases 1 and 3 were kindly pointed out to the author by other physicians, cases 4 and 5 surfaced as a result of a nation-wide study of Hodgkin's disease (Nordentoft et al., 1980) , and cases 9 and 10 were found as a result of an epidemiological study of 2,544 patients with respiratory sarcoidosis (Brincker & Wilbek, 1974 (Brincker, 1972) Nine cases of associated neoplastic disease were found, 7 of which were malignant tumours (Table  IV) . Remarkably, these 9 cases occurred in only 5 patients. The case of acute myelocytic leukaemia may have been iatrogenic, following 10 years of chlorambucil treatment. Further, this patient had had several courses of 165KVX-ray therapy in 1942-43 because of furunculosis. Five of the 17 malignant tumours occurred after the diagnosis of sarcoidosis and 2 before. The total number of cases of malignant tumours expected to occur in all 17 patients was calculated both for the period of birth to last date of observation and for the period of onset of sarcoidosis to last day of observation, using published Danish incidence figures (Danish Cancer Registry, 1982) . Table V shows that significantly more malignant tumours occurred than expected (P= <0.05), regardless of the method of calculation.
Discussion
The three features of the proposed sarcoidosislymphoma syndrome apparent from the literature review (Table I) were all confirmed by the present study, viz. that LD always occurs after sarcoidosis, that the median age at onset of sarcoidosis is 10 years above that of unselected sarcoidosis patients, and that Hodgkin's disease occurs more frequently than expected.
The median interval from the onset of sarcoidosis was almost 4 times longer than in the previously reported cases, 95 versus 24 months. Whether this interval is shorter in Hodgkin's disease and in nonHodgkin's lymphoma than in chronic lymphocytic leukaemia and paraproteinaemia is uncertain due to the small number of cases. The relatively long interval from sarcoidosis to LD found in the present study may simply reflect the author's interest in following up anamnestic leads of preceding sarcoidosis in lymphoma patients. In none of the 17 cases did LD precede sarcoidosis. Cases 1 and 2 of Table II are really no exception to this rule since EPCG were demonstrated concomitantly with LD although the clinical manifestations of sarcoidosis did not appear until later.
The impression that the sarcoidosis-lymphoma syndrome is associated with a chronic active type of sarcoidosis appears to have been confirmed by the present study. Thus, the median age of the patients was rather high (41 years as in previously reported cases), they had long-term lymphopenia, 85% were anergic, 53% had received corticosteroid treatment, and 71% had signs of persistent disease activity. These factors are usually associated with significant immunologic abnormalities typical of sarcoidosis, viz. an increased number of T helper cells in granulomatous tissues, a decreased number of circulating T helper cells, and hyperactivity of the B cell system (Daniele et al., 1980) . There were twice as many cases of Hodgkin's disease as of non-Hodgkin's lymphoma in the present study whereas the latter type of lymphoma dominated among the previously reported cases (15 versus 10, Table I ). The reason for this discrepancy is not clear. In any case, Hodgkin's disease occurs more frequently than expected. This agrees with a previous epidemiological study of cancer incidence in 2,544 patients with respiratory sarcoidosis. Here 6 cases of malignant lymphoma occurred against 0.52 cases expected. Four cases were Hodgkin's disease and 2 non-Hodgkin's lymphoma (Brincker & Wilbek, 1974) . It is puzzling why both true sarcoidosis and local sarcoid reactions should be associated particularly with one type of LD (Kadin et al., 1971; Kim & Dorfman, 1974; Neiman, 1977) . However, all combinations of sarcoidosis and LD appear to occur (Tables I and II) with the possible exception of acute lymphocytic leukaemia.
The finding of a significantly increased incidence of various malignant tumours is at variance both with previously reported cases and with the aforementioned epidemiological study in which lung cancer was the only malignancy apart from LD occurring more frequently than expected with 9 cases observed versus 2.8 expected (Brincker & Wilbek, 1974) . It is interesting, however, that whereas the median age at onset of sarcoidosis among all the 2,544 cases in the previous study was 30 years, it was 56 years in those 24 patients who subsequently developed a malignant tumour other than LD (unpublished observations). Thus, here as in LD there is a suggestion that it is the chronic active type of sarcoidosis developing in middle-aged patients which is associated with subsequent development of malignant disease.
The chronology of sarcoidosis, LD and other malignant tumours viewed together with the evidence of immunological abnormalities in the patients studied (anergy, lymphopenia, persistent disease activity) makes it natural to look for immunological mechanisms behind the sarcoidosislymphoma syndrome. It has long been known that patients with congenital or acquired immunodeficiency syndromes and with certain immunoinflammatory diseases often develop lymphomas, and it has been proposed that the increased mitotic activity of lymphocytes increases their risk of mutation and subsequent malignant transformation, because a failure exists of feedback mechanisms to regulate lymphocyte proliferation (Louie & Schwartz, 1978) . Since the mitotic activity of lymphocytes appears to be increased also-in sarcoidosis due to the immune inflammatory response in the involved tissues (Daniele et al., 1980) , sarcoidosis probably belongs to the group of lymphoma-associated diseases mentioned. It is more difficult to explain the increased incidence of malignant tumours other than LD in sarcoidosis. However, the depletion of circulating T helper cells might lead to decreased tumour rejection (Vose & Moore, 1985) or perhaps to decreased resistance against oncogenic viruses. In this context it may be significant that 6 of the 9 neoplasms found in the patients studied (Table IV) and the excess cases of lung cancer found in the previous study (Brincker & Wilbek, 1974) originated from surface epithelium of the respiratory tract, the skin, and the female genital tract -all sites that are frequently exposed to various carcinogenic stimuli.
Although the present study was not designed to answer the question whether more cases of LD are observed in sarcoidosis than expected, it allows some estimates to be made. The prevalence of sarcoidosis in Scandinavia has been found to be in the range of 7.5-64/100,000, but it may be higher (Sharma, 1984; Teirstein & Lesser, 1983 ). If we use the upper figure of 64/100,000, the total number of cases of sarcoidosis in Denmark (with a population of 5 million people) would be 3,200. The yearly incidence of LD is about 1 in 5,000 -in other words, 0.64 cases of LD should be expected to occur yearly in patients with sarcoidosis as a result of chance alone. Since 11 of the 17 patients in the present study were collected over a 17-year period from an underlying population representing 18% of the Danish population, this corresponds to about 60 patients for the entire country over a 17-year period, or 3.5 patients yearly. Thus, the observed number of cases appears to be about 5.5 times the expected number, which supports the hypothesis of sarcoidosis as a predisposing factor for LD. The 5.5/1 ratio is lower than the 11.5/1 ratio found in the previous epidemiological study (Brincker & Wilbek, 1974) , and the correct figure may lie in between since both methods of calculation are hampered by uncertainties.
In conclusion, a sarcoidosis-lymphoma syndrome appears to exist in which LD and other malignancies develop more often than expected in middle-aged patients with chronic active sarcoidosis, perhaps as a consequence of the immunologic abnormalities observed in the latter disease.
